Clinical Trials · NCT07812597
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
- Enrollment
- 210
- Start date
- Oct 2026
- Locations
- 16 sites, China
- Primary endpoint
- Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomization